| 17.89 0.19 (1.07%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 21.82 | 1-year : | 23.71 |
| Resists | First : | 18.68 | Second : | 20.29 |
| Pivot price | 17.53 |
|||
| Supports | First : | 16.07 | Second : | 13.37 |
| MAs | MA(5) : | 17.88 |
MA(20) : | 17.29 |
| MA(100) : | 19.08 |
MA(250) : | 18.1 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 42.4 |
D(3) : | 42.9 |
| RSI | RSI(14): 52.5 |
|||
| 52-week | High : | 22.5 | Low : | 14.14 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MDWD ] has closed below upper band by 37.3%. Bollinger Bands are 0.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.12 - 18.2 | 18.2 - 18.28 |
| Low: | 17.27 - 17.37 | 17.37 - 17.46 |
| Close: | 17.74 - 17.9 | 17.9 - 18.03 |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Thu, 25 Sep 2025
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia - GlobeNewswire
Thu, 25 Sep 2025
Now Approved in 45 Countries: MediWound's Revolutionary NexoBrid Burn Treatment Enters Australian Market - Stock Titan
Wed, 24 Sep 2025
MediWound (NASDAQ:MDWD) Stock Passes Below 50 Day Moving Average - What's Next? - MarketBeat
Tue, 02 Sep 2025
MediWound Is A Buy Opportunity On The Dip (NASDAQ:MDWD) - Seeking Alpha
Wed, 20 Aug 2025
Enzymatic Therapeutics Leader MediWound to Present Latest Developments at Global Investment Conference - Stock Titan
Thu, 14 Aug 2025
MediWound Reports Strong Growth as Global Wound Care Partners Join Clinical Trials - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 11 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 17.8 (%) |
| Held by Institutions | 44.7 (%) |
| Shares Short | 871 (K) |
| Shares Short P.Month | 819 (K) |
| EPS | -2.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.85 |
| Profit Margin | -142.2 % |
| Operating Margin | -100.2 % |
| Return on Assets (ttm) | -22.3 % |
| Return on Equity (ttm) | -148.7 % |
| Qtrly Rev. Growth | 12.6 % |
| Gross Profit (p.s.) | 0.33 |
| Sales Per Share | 1.82 |
| EBITDA (p.s.) | -1.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -6.89 |
| PEG Ratio | 0 |
| Price to Book value | 9.67 |
| Price to Sales | 9.8 |
| Price to Cash Flow | -12.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|